The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Pentoxifylline in the Treatment of Radiation-Induced Fibrosis
Abstract
Purpose: Fibrotic sequelae remain the most important dose-limiting toxicity of radiation therapy to soft tissue. Functionally, this is reflected in loss of range of motion and muscle strength and the development of limb edema and pain. Tumor necrosis factor alpha and fibroblast growth factor 2 (FGF2), which are abnormally elevated in irradiated tissues, may mediate radiation fibrovascular injury. Patients and Methods: In an open label drug trial, we studied the effects of pentoxifylline (400 mg orally tid for 8 weeks) on 30 patients who displayed late, radiation-induced fibrosis at 1 to 29 years posttreatment (40 to 84 Gy). The primary outcome measurement was change in physical impairments thought to be secondary to radiation, including active and passive range of motion (AROM and PROM), muscle strength, limb edema, and pain. Plasma levels of cytokines (tumor necrosis factor alpha and FGF2) also were measured. Twenty-seven patients completed baseline and 8-week assessments, and 24 patients completed baseline, 8-week, and 16-week assessments. Results: After 8 weeks of pentoxifylline intervention, 20 of 23 patients with impaired AROM and 19 of 22 with impaired PROM improved; 11 of 19 patients with muscle weakness showed improved motor strength; five of seven patients with edema had decreased limb girth; and nine of 20 patients had decreased pain. Pretreatment FGF2 levels dropped from an average of 44.9 pg/mL to 24.0 pg/mL after 8 weeks of treatment. Conclusion: Patients receiving pentoxifylline demonstrated improved AROM, PROM, and muscle strength and decreased limb edema and pain. Reversal of these delayed radiation effects was associated with a decrease in circulating FGF2.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Piguet, P. F., Vesin, C., Grau, G. E., & Thompson, R. C. (1993) · Cytokine · doi:10.1016/1043-4666(93)90024-y · Cited by 215
Cited by
Runowicz, C. D., Leach, C. R., Henry, N. L., Henry, K. S., Mackey, H. T., Cowens-Alvarado, R. L., Cannady, R. S., Pratt-Chapman, M. L., Edge, S. B., Jacobs, L. A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.3809 · Cited by 1,071
Runowicz, C. D., Leach, C. R., Henry, N. L., Henry, K. S., Mackey, H. T., Cowens‐Alvarado, R. L., Cannady, R. S., Pratt‐Chapman, M. L., Edge, S. B., Jacobs, L. A., et al. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21319 · Cited by 728
Selenium and the Course of Mild Graves' Orbitopathy
Marcocci, C., Kahaly, G. J., Krassas, G. E., Bartalena, L., Prummel, M., Stahl, M., Altea, M. A., Nardi, M., Pitz, S., Boboridis, K., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1012985 · Cited by 619
Impairment‐driven cancer rehabilitation: An essential component of quality care and survivorship
Silver, J. K., Baima, J., & Mayer, R. S. (2013) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21186 · Cited by 431
Animal Models for Medical Countermeasures to Radiation Exposure
Williams, J. P., Brown, S. L., Georges, G. E., Hauer-Jensen, M., Hill, R. P., Huser, A. K., Kirsch, D. G., MacVittie, T. J., Mason, K. A., Medhora, M. M., et al. (2010) · Radiation Research · doi:10.1667/rr1880.1 · Cited by 423
Self-citation
Metadata
- Authors
- Okunieff, P., Augustine, E., Hicks, J. E., Cornelison, T. L., Altemus, R. M., Naydich, B. G., Ding, I., Huser, A. K., Abraham, E. H., Smith, J. J., Coleman, N., & Gerber, L. H.
- Venue
- Journal of Clinical Oncology
- Published
- 2004-06-01
- Volume
- 22
- Issue
- 11
- Pages
- 2207-2213
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2130679532
- Cited by
- 163
- References
- 1
- FWCI
- 6.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pentoxifylline in the Treatment of Radiation-Induced Fibrosis. https://app.cochat.ai/papers/10.1200/jco.2004.09.101
- The paper
- Okunieff, P., Augustine, E., Hicks, J. E., Cornelison, T. L., Altemus, R. M., Naydich, B. G., Ding, I., Huser, A. K., Abraham, E. H., Smith, J. J., Coleman, N., & Gerber, L. H. (2004). Pentoxifylline in the Treatment of Radiation-Induced Fibrosis. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2004.09.101
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.